4-[2-(1-benzimidazolyl)ethoxy]phenol | 80200-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-[2-(1-benzimidazolyl)ethoxy]phenol
• 英文别名: 4-[2-(1H-Benzimidazol-1-yl)ethoxy]phenol；4-[2-(benzimidazol-1-yl)ethoxy]phenol
• CAS: 80200-00-6
• 化学式: C₁₅H₁₄N₂O₂
• 分子量: 254.288
• InChiKey: YCONEPHMWFPQSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  47.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[2-(1-benzimidazolyl)ethoxy]phenol 在 sodium hydride 作用下， 以 乙醇 为溶剂， 反应 18.58h， 生成 1-[4-[2-(1-benzimidazolyl)ethoxy]phenoxy]-3-isopropylamino-2-propanol
  参考文献：
  名称：

  .beta.1-Selective adrenoceptor antagonists. 3. 4-Azolyl linked phenoxypropanolamines

  摘要：

  A series of 4-substituted phenoxypropanolamines has been prepared and examined for beta-adrenoceptor activity. The 4-substituents, di- and triazole ring systems connected to the phenoxy ring by different length chains, were chosen as a means of introducing cardioselectivity. This has been achieved, especially in the 1-[4-[(4-chloropyrazol-1-yl)methoxy] phenoxy]-3-(isopropylamino)-2-propanol (11), the 4-[(2H-1,2,3-triazol-2-yl)methoxy] analogue (21), and the 4-[2-(2H-1,2,3-triazol-2-yl)ethoxy] analogue (22), which show potent beta 1-blockade with selectivity ratios in excess of 100:1. Structure-activity relationships are discussed, and the optimum position of the heteroatom in the 4-substituent is defined.

  DOI：

  10.1021/jm00370a012
• 作为产物：
  描述：

  1-苄氧基-4-(2-溴乙氧基)苯 在 palladium on activated charcoal 氢气 、 sodium hydride 作用下， 以 乙醇 为溶剂， 25.0~60.0 ℃ 、101.33 kPa 条件下， 反应 0.58h， 生成 4-[2-(1-benzimidazolyl)ethoxy]phenol
  参考文献：
  名称：

  .beta.1-Selective adrenoceptor antagonists. 3. 4-Azolyl linked phenoxypropanolamines

  摘要：

  A series of 4-substituted phenoxypropanolamines has been prepared and examined for beta-adrenoceptor activity. The 4-substituents, di- and triazole ring systems connected to the phenoxy ring by different length chains, were chosen as a means of introducing cardioselectivity. This has been achieved, especially in the 1-[4-[(4-chloropyrazol-1-yl)methoxy] phenoxy]-3-(isopropylamino)-2-propanol (11), the 4-[(2H-1,2,3-triazol-2-yl)methoxy] analogue (21), and the 4-[2-(2H-1,2,3-triazol-2-yl)ethoxy] analogue (22), which show potent beta 1-blockade with selectivity ratios in excess of 100:1. Structure-activity relationships are discussed, and the optimum position of the heteroatom in the 4-substituent is defined.

  DOI：

  10.1021/jm00370a012

文献信息

• Substituted phenoxy-aminopropanol derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04387100A1

  公开（公告）日：1983-06-07

  Phenoxy-aminopropanol derivatives of the formula ##STR1## wherein R is lower alkyl, X is oxygen or sulfur, n is the integer zero or 1, Y is methylene, ethylene or propylene or, when n is zero, Y can also be a group of the formula --CH.dbd.CH--C*H.sub.2 -- (a) , wherein the double-bond is trans and the carbon atom marked with an asterisk is linked to Z, and Z is a 5-membered aromatic heterocyclic ring which contains one or more nitrogen atoms as the sole hetero atom (s), said heterocyclic ring is linked to Y via a nitrogen atom, and may be substituted by halogen, lower alkyl, lower alkoxy, aryl, cyano or carboxamido, or on adjacent carbon atoms by a group of the formula ##STR2## and pharmaceutically acceptable acid addition salts thereof are described. A process for the preparation of the compound of formula I and pharmaceutical preparations containing them are also described. The aforementioned compounds and salts possess .beta.-adrenergic blocking activity and antihypertensive activity.

  化合物的结构式为##STR1##其中，R是低碳基，X是氧或硫，n是整数0或1，Y是亚甲基，乙烯基或丙烯基，当n为零时，Y也可以是式--CH.dbd.CH--C*H.sub.2 --（a）的基团，其中双键是反式的，带有星号的碳原子连接到Z，Z是一个含有一个或多个氮原子作为唯一杂原子的5元芳杂环，所述杂环通过一个氮原子与Y连接，并且可以被卤素，低碳基，低碳氧基，芳基，氰基或羧酰胺取代，或在相邻的碳原子上被式##STR2##的基团所取代，以及其药学上可接受的酸加盐。还描述了制备式I化合物的过程和含有它们的药物制剂。上述化合物和盐具有β-肾上腺素能阻滞活性和降压活性。
• Azolyl-substituted phenoxy-aminopropanol derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04577030A1

  公开（公告）日：1986-03-18

  Phenoxy-aminopropanol derivatives of the formula ##STR1## wherein R is lower alkyl, X is oxygen or sulfur, n is the integer zero or 1, Y is methylene, ethylene or propylene or, when n is zero, Y can also be a group of the formula ##STR2## wherein the double-bond is trans and the carbon atom marked with an asterisk is linked to Z, and Z is a 5-membered aromatic heterocyclic ring which contains one or more nitrogen atoms as the sole hetero atom (s), said heterocyclic ring is linked to Y via a nitrogen atom, and may be substituted by halogen, lower alkyl, lower alkoxy, aryl, cyano or carboxamido, or on adjacent carbon atoms by a group of the formula --(CH.sub.2).sub.4 -- (b) or --CH.dbd.CH--CH.dbd.CH--, (c) and pharmaceutically acceptable acid addition salts thereof are described. A process for the preparation of the compound of formula I and pharmaceutical preparations containing them are also described. The aforementioned compounds and salts possess .beta.-adrenergic blocking activity and antihypertensive activity.

  公式为##STR1##的Phenoxy-aminopropanol衍生物，其中R为较低的烷基，X为氧或硫，n为整数零或1，Y为亚甲基，乙烯基或丙烯基，或者当n为零时，Y也可以是一个公式##STR2##中的一个基团，其中双键为反式，带星号的碳原子与Z连接，Z为一个5-成员芳香杂环环，其中包含一个或多个氮原子作为唯一的杂原子（S），所述杂环环通过氮原子与Y连接，并且可以被卤素，较低的烷基，较低的烷氧基，芳基，氰基或羧酰胺基取代，或在相邻的碳原子上由公式--（CH.sub.2）.sub.4--（b）或--CH.dbd.CH--CH.dbd.CH--（c）的基团取代，并且其药物可接受的酸盐也被描述。还描述了制备公式I化合物和含有它们的制药制剂的过程。上述化合物和盐具有β-肾上腺素能阻滞活性和降压活性。
• US4387100A
  申请人：——

  公开号：US4387100A

  公开（公告）日：1983-06-07
• US4577030A
  申请人：——

  公开号：US4577030A

  公开（公告）日：1986-03-18
• US4663462A
  申请人：——

  公开号：US4663462A

  公开（公告）日：1987-05-05